Loading AI tools
Vaccine against COVID-19 From Wikipedia, the free encyclopedia
FAKHRAVAC (Persian: واکسن فخرا) is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research,[1] a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials.[1][2][3] It is currently in phase III.[4][5] It received emergency use authorization in Iran on 9 September 2021.[4]
![]() A vial of FakhraVac | |
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | Fakhra, MIVAC |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
|
The vaccine is named after the Iranian nuclear scientist Mohsen Fakhrizadeh.[1] According to the Iranian authorities, he was working on a vaccine in response to the COVID-19 pandemic in Iran.[1][6] Fakhrizadeh was assassinated in November 2020 in an attack Iran and US intelligence attributed to Israel.[1][7]
It requires two doses given by intramuscular injection 3 weeks apart.[5]
FAKHRAVAC is an inactivated virus-based vaccine.[3]
In August 2021, production capacity of the vaccine was reported to be 1 million dose per month and was planned to be "multiplied in a few months ".[4] In October 2021, the production was reported to be stopped amid Iran's growing vaccine imports.[8] In January 2022, the Director General of Health of the Ministry of Defense announced that the first shipment (around 462,000 doses) of the vaccine had been delivered to the Iranian Ministry of Health.[9]
Phase | Registration number | Start | Number of participants | Age of participants | ||
---|---|---|---|---|---|---|
Total | Vaccine | Control | ||||
I | IRCT20210206050259N1 Archived 28 April 2021 at the Wayback Machine | 8 March 2021 | 135 | 96? | 39? (placebo) | 18–55 years |
II | IRCT20210206050259N2 Archived 16 June 2021 at the Wayback Machine | 8 June 2021 | 500 | 250 | 250 (placebo) | 18–70 years |
III | IRCT20210206050259N3 Archived 7 September 2021 at the Wayback Machine | 29 August 2021 | 41,128 | 20,564 | 20,564 (Sinopharm BIBP vaccine) | >18 years |
FAKHRAVAC received emergency use authorization in Iran on 9 September 2021.[4] In October 2021, Iran's Food and Drug Administration was considering giving full authorization to the vaccine for third/booster dose.[8]
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.